Authors
Latest:
Navigating Digital Transformation Fatigue: The Strategy for Success in Regulated IndustriesDigital transformation initiatives are often complex endeavors that can significantly impact the way organizations operate.
Latest:
The True Reliability of Real-World DataOutlining five questions that should be considered when assessing if RWD is “fit for purpose” in pharma research—and ultimately clinical and pharmacy decision support
Latest:
Harnessing the Potential of Data to Deliver the Future of HealthcareFaster approvals, more accurate and timely medicines monitoring—all enabled by harmonized, consistent and reliable data—will drive improved patient outcomes.
Latest:
Developing Your Roadmap to Pharma 4.0Questions to ask before transitioning into new technologies. By Yvonne Duckworth and Cory Perelman.
Latest:
Patient Centricity in the Pharma Supply ChainThe importance of industry, as it moves forward, in focusing on patient-centered care and prioritizing patient needs across the supply chain.
Latest:
The Evolving Value Assessment Landscape in the USHow current frameworks influence coverage decisions and pricing negotiations.
Latest:
What Makes Hub Programs Successful?Outlining the core functional skill sets of the most effective hub programs—all toward the goal of helping patients get on prescriptions as quickly as possible
Latest:
Telehealth: Connecting the DotsHow pharma can speed up the journey with direct-to-patient models
Latest:
Maximizing HCP engagement as the definition of a sales ‘call’ expandsHow pharma’s retooling of its promotional efforts in the post-pandemic era impacts sizing and targeting, two crucial foundational pieces to successful commercialization
Latest:
After a Decade of Regulatory Transformation, What’s Next?Following a decade of solid groundwork to modernize regulatory information management in life sciences, leading companies have now shifted their focus to how they might exploit this new digital landscape
Latest:
Global Study Warns Cancer Cases to Triple in Low-HDI Countries by 2050, Urging Enhanced Prevention, Care InitiativesBy 2050, study estimates that cancer incidence and mortality rates will nearly triple in low-Human Development Index countries, highlighting an urgent need for enhanced global cancer prevention, early detection, and treatment strategies to address growing disparities.
Latest:
Succeeding with Fit-for-Purpose AIHow artificial intelligence is improving the patient experience
Latest:
Drug Shortages: A Chronic Problem, but New Opportunities Present ThemselvesWhile this concern is causing ripples in the global supply chain, technological and regulatory advances can help address the issue
Latest:
Developing a Successful Data & Analytics Strategy: Four Common QuestionsA comprehensive data and analytics strategy is now table stakes for pharmaceutical and life science organizations, writes Simon Andrews
Latest:
The Impact of 340B on Commercial ContractsDuplicate rebates have resulted in revenue leakage for manufacturers.
Latest:
Congress Leaves Town with Major Drug-Related Bills on HoldPandemic preparedness and curbing PBMs among the pending legislation that will have to wait until after summer recess.
Latest:
What’s Next for Biopharma Under the Inflation Reduction ActAs we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry.
Latest:
The Rise of GLP-1 Drugs and the Challenges of Proper DisposalWith great power comes great responsibility. In this case, tackling these obstacles is vital to making sure that the positives of GLP-1s are not outweighed by the downfalls of improper waste disposal.
Latest:
Positioning the Patient in Drug TrialsThe clinical research industry must integrate feedback from patients and sites to eliminate unnecessary burden and accelerate enrollment in clinical trials
Latest:
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Latest:
Developing Your Roadmap to Pharma 4.0Questions to ask before transitioning into new technologies. By Yvonne Duckworth and Cory Perelman.
Latest:
Exploring the Digital Therapeutics LandscapeObservations from recent digital health events and a glimpse of what’s ahead—from Milan to Boca Raton
Latest:
What is a Digital Hub in 2023?Deciphering the different "technology-first” and “technology-enabled” patient support programs.
Latest:
Seeing the Value of Scientific ContentLeveraging the value healthcare professionals place on scientific content
Latest:
Strategizing High-Wire, Multi-Indication LaunchesProperly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.
Latest:
Chatbot Potential in Clinical ResearchHow AI-powered support automation can solve the data problem in clinical trial management
Latest:
Is Trust the Secret Ingredient for Digital Product Success?To rebuild trust, companies should utilize a customer-centric approach, focusing on transparent and neutral content incorporating medical expertise and regularly seeking HCP feedback.
Latest:
Global Logistics: A Cold Chain BlueprintThe growing pipeline of cold chain products holds tremendous promise for patients, but can result in failed shipments if not properly planned for
Latest:
Why Multimodal Data is Growing in PharmaMaking connections between different datasets is essential to developing impactful medicines and driving more personalized patient care.
Latest:
Flipping the Switch on DSCSA InteroperabilityFrom November 2023, the Drug Supply Chain Security Act requires healthcare manufacturers, distributors, providers, and dispensers to exchange the serialized item-level product information that has been collected, standardized, and digitized. Hitting this deadline hinges on intensive collaboration between manufacturers and their supply chain partners that must begin now
